Immunological Mechanisms of Interstitial Disease

Danoff, Theodore M.

doi:10.1016/b978-012088488-9.50089-9

Cited by 1 publication

(1 citation statement)

References 376 publications

(276 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Replacement fibrosis involves the replacement of necrotic, severely inflamed, or damaged cardiac tissue following acute cardiac injury; this is seen, for instance, following myocardial infarction [5,6]. Reactive fibrosis usually occurs as a reaction to changes in myocardial load, and this form of fibrosis typically occurs in the absence of cell loss in the myocardium [7][8][9]. Reduced cardiac output, risk of arrhythmia, myocardial stiffness, diastolic dysfunction, and the development of heart failure are major abnormalities associated with pathological fibrotic remodeling and could ultimately result in sudden death of the affected patients [8].…”

Section: Introductionmentioning

confidence: 99%

Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect

Majid

Hassan

Hoque

et al. 2023

JCDD

View full text Add to dashboard Cite

Cardiac fibrosis is a pathological condition characterized by excessive deposition of collagen and other extracellular matrix components in the heart. It is recognized as a major contributor to the development and progression of heart failure. Despite significant research efforts in characterizing and identifying key molecular mechanisms associated with myocardial fibrosis, effective treatment for this condition is still out of sight. In this regard, bioactive compounds have emerged as potential therapeutic antifibrotic agents due to their anti-inflammatory and antioxidant properties. These compounds exhibit the ability to modulate fibrogenic processes by inhibiting the production of extracellular matrix proteins involved in fibroblast to myofibroblast differentiation, or by promoting their breakdown. Extensive investigation of these bioactive compounds offers new possibilities for preventing or reducing cardiac fibrosis and its detrimental consequences. This comprehensive review aims to provide a thorough overview of the mechanisms underlying cardiac fibrosis, address the limitations of current treatment strategies, and specifically explore the potential of bioactive compounds as therapeutic interventions for the treatment and/or prevention of cardiac fibrosis.

show abstract